63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization

Post-Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder (PTSD) is a debilitating, chronic psychiatric condition triggered by exposure to severe traumatic stressors. In primary care settings, PTSD is frequently underdiagnosed because patients often present with somatic complaints, unexplained pain, sleep disturbances, or comorbid substance use rather than explicitly volunteering traumatic memories.

Neurobiology & Pathophysiology

PTSD is conceptualized as a disorder of fear conditioning, extinction learning, and emotional regulation mediated by disrupted neural circuitry:

• Amygdala Hyperactivity: The basolateral amygdala exhibits heightened baseline firing and exaggerated reactivity to trauma-related and neutral threat cues, driving hyperarousal, hypervigilance, and acute autonomic panic.
• Prefrontal Cortex (vmPFC & ACC) Hypoactivity: The ventromedial prefrontal cortex (vmPFC) and anterior cingulate cortex (ACC) normally exert top-down inhibitory control over amygdalar hyperresponsiveness. In PTSD, hypoactivity in these structures leads to failed fear extinction learning, permitting conditioned fear memories to persist unchecked.
• Hippocampal Volume Reduction: Reduced hippocampal volume and impaired neurogenesis disrupt contextual processing. Patients cannot contextualize memories as belonging to the past; instead, traumatic memories are experienced in the present moment as vivid, intrusive flashbacks.
• Neuroendocrine & Autonomic Dysregulation: Unlike major depression (which features sustained hypercortisolemia), PTSD is often characterized by enhanced glucocorticoid receptor sensitivity, resulting in low-to-normal baseline plasma cortisol with blunted cortisol awakening responses alongside chronically elevated central corticotropin-releasing factor (CRF). Concurrently, hyperactivation of the locus coeruleus noradrenergic system sustains excessive peripheral and central sympathetic tone, manifesting as resting tachycardia, diaphoresis, and sleep-disrupting nightmares.

                  NEUROBIOLOGICAL CIRCUITRY OF PTSD

     [ Traumatic Trigger / Conditioned Cue ]
                       │
                       ▼
   ┌────────────────────────────────────────┐
   │        HYPERACTIVE AMYGDALA            │ ──> Sympathetic Autonomic Surge
   │  • Unfiltered threat appraisal         │     (Tachycardia, Diaphoresis, Panic)
   │  • Exaggerated startle response        │ ──> Emotional Reactivity & Fear
   └───────────────────▲────────────────────┘
                       │ FAILED INHIBITION
   ┌───────────────────┴────────────────────┐
   │   HYPOACTIVE PREFRONTAL CORTEX (vmPFC) │ ──> Failed fear extinction learning
   │   & ANTERIOR CINGULATE CORTEX (ACC)    │     (Inability to suppress panic)
   └────────────────────────────────────────┘
                       │ IMPAIRED CONTEXT
   ┌───────────────────┴────────────────────┐
   │     HIPPOCAMPAL VOLUME LOSS & ATROPHY   │ ──> Loss of chronological context
   │  • Defective episodic memory retrieval │     (Flashbacks experienced as NOW)
   └────────────────────────────────────────┘

---

DSM-5 Diagnostic Criteria for PTSD

A formal diagnosis of PTSD under DSM-5 requires exposure to a traumatic event followed by persistent symptoms spanning four discrete symptom clusters lasting >1 month, causing clinically significant distress or functional impairment:

                    DSM-5 DIAGNOSTIC CRITERIA FOR PTSD

   Diagnostic Category       Required Criteria & Clinical Manifestations
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════
   Criterion A               Exposure to actual or threatened death, serious injury, or sexual violence
   (Trauma Exposure)         through: 1) Direct experience; 2) Witnessing in person; 3) Learning event
                             occurred to close family/friend (violent/accidental); or 4) Repeated/extreme
                             aversive exposure to trauma details (e.g., first responders, forensic workers).
                             *Note: Media exposure does not qualify unless work-related.
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Criterion B               ≥1 Intrusion Symptom:
   (Intrusion)               • Recurrent, involuntary, intrusive distressing memories of the trauma.
                             • Distressing recurrent trauma-related dreams/nightmares.
                             • Dissociative reactions (e.g., flashbacks) where trauma feels recurring.
                             • Intense psychological distress upon exposure to trauma cues.
                             • Marked physiological reactivity to internal or external trauma cues.
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Criterion C               ≥1 Avoidance Symptom:
   (Avoidance)               • Avoidance of internal trauma thoughts, feelings, or memories.
                             • Avoidance of external reminders (people, places, conversations, activities).
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Criterion D               ≥2 Negative Alterations in Cognitions and Mood:
   (Negative Cognitions      • Dissociative amnesia (inability to recall key trauma features; not TBI/drugs).
   & Mood)                   • Persistent, exaggerated negative beliefs about oneself/world ('I am ruined').
                             • Distorted cognitions leading to persistent self-blame or blaming others.
                             • Persistent negative emotional state (fear, horror, guilt, anger, shame).
                             • Markedly diminished interest/participation in significant activities.
                             • Feelings of detachment or estrangement from others.
                             • Persistent inability to experience positive emotions (love, joy, satisfaction).
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Criterion E               ≥2 Alterations in Arousal and Reactivity:
   (Arousal &                • Irritable behavior and angry outbursts (with little/no provocation).
   Reactivity)               • Reckless or self-destructive behavior.
                             • Hypervigilance.
                             • Exaggerated startle response.
                             • Concentration difficulties.
                             • Sleep disturbance (difficulty initiating/maintaining sleep, restless sleep).
   ──────────────────────────────────────────────────────────────────────────────────────────────────────
   Duration & Impact         • Criterion F: Duration of symptoms >1 month.
                             • Criterion G: Clinically significant distress or impairment (social, work).
                             • Criterion H: Not attributable to substance use or a medical condition.
   ══════════════════════════════════════════════════════════════════════════════════════════════════════════

Acute Stress Disorder (ASD) vs. PTSD

• Acute Stress Disorder: Diagnosed when a patient meets symptom criteria spanning intrusion, negative mood, dissociation, avoidance, and arousal persisting between 3 days and 1 month following trauma exposure.
• Diagnostic Transition: If symptoms resolve within 30 days, the diagnosis remains ASD. If symptoms persist beyond 1 month, the diagnosis is formally reclassified as PTSD. Patients with severe ASD carry an 80% risk of progressing to chronic PTSD if left untreated.

Screening in Primary Care: The PC-PTSD-5

The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) is a validated 5-item screening tool designed for outpatient clinical practice. It begins with an initial trauma exposure inquiry; if affirmed, the patient answers 5 yes/no questions reflecting re-experiencing, avoidance, hyperarousal, emotional numbness, and guilt. A score of ≥3 or ≥4 points constitutes a positive screen and mandates a comprehensive clinical diagnostic interview.

---

Evidence-Based Treatment of PTSD

1. First-Line Psychotherapy (Gold Standard)

Psychotherapy is the primary, most effective treatment for PTSD, displaying superior long-term remission rates compared to pharmacotherapy alone:

• Trauma-Focused Cognitive Behavioral Therapy (TF-CBT): Combines psychoeducation, cognitive restructuring of distorted trauma-related beliefs (e.g., survivor guilt, overgeneralized mistrust), and graded exposure.
• Prolonged Exposure (PE): Utilizes systematic, repeated imaginal exposure (revisiting the trauma memory in detail) and in vivo exposure (gradually approaching safe, real-world situations avoided due to trauma triggers) to achieve fear habituation and extinction.
• Eye Movement Desensitization and Reprocessing (EMDR): Combines patient recall of distressing trauma memories with bilateral sensory stimulation (saccadic eye movements, alternating auditory tones, or tactile taps) to facilitate adaptive neurocognitive memory reprocessing.

2. First-Line Pharmacotherapy

When psychotherapy is inaccessible, declined, or only partially effective, pharmacotherapy is indicated:

• Selective Serotonin Reuptake Inhibitors (SSRIs): Sertraline (start 25-50 mg daily, titrate to 100-200 mg daily) and Paroxetine (start 20 mg daily, titrate to 40-50 mg daily) are the two medications carrying FDA approval for PTSD. Fluoxetine (20-60 mg daily) also exhibits robust evidence.
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine ER (start 37.5-75 mg daily, titrate to 150-225 mg daily) possesses strong randomized trial evidence and is widely recognized as a first-line alternative.
• Dosing Strategy: Start at low doses to minimize initial noradrenergic agitation or jitteriness, and titrate over 8-12 weeks. Pharmacotherapy should continue for at least 6-12 months following symptom remission before considering a slow taper.

3. Management of Trauma Nightmares & Sleep Disruption: Prazosin

Trauma nightmares and nocturnal awakenings are driven by excessive noradrenergic outflow from the locus coeruleus during rapid eye movement (REM) sleep:

• Agent & Mechanism: Prazosin is a lipid-soluble, centrally active alpha-1 adrenergic receptor antagonist. By crossing the blood-brain barrier and competitively blocking post-synaptic alpha-1 receptors, prazosin dampens central sympathetic overdrive, normalizes REM sleep architecture, and reduces or eliminates trauma nightmares.
• Titration Protocol: Initiate at 1 mg orally at bedtime to prevent first-dose syncope. Titrate upward by 1-2 mg every 3-7 days based on nightmare suppression and tolerability. Typical effective doses range from 2-6 mg at bedtime in women and 6-15 mg at bedtime in men (divided doses can be used in refractory combat veterans).
• Adverse Effects & Monitoring: Orthostatic hypotension, dizziness, reflex tachycardia, and dry mouth. Baseline and standing blood pressure must be monitored during dose titration.

4. Strict Contraindication: Benzodiazepines in PTSD

[!CAUTION] Benzodiazepines (e.g., alprazolam, clonazepam, lorazepam, diazepam) are STRICTLY NOT RECOMMENDED for PTSD.

• Impaired Fear Extinction: Benzodiazepines potentiate GABA-A signaling in the amygdala and prefrontal cortex, actively inhibiting the neuroplasticity required for fear extinction and emotional processing during psychotherapy.
• Worse Clinical Outcomes: Meta-analyses demonstrate that patients prescribed benzodiazepines exhibit higher long-term PTSD severity, higher rates of depression, and greater treatment dropout.
• Substance Misuse & Disinhibition: Because PTSD frequently co-occurs with alcohol and substance use disorders, benzodiazepine therapy carries high addiction potential, tolerance, physical dependence, and risk of paradoxical disinhibition or accidental fatal overdose.

---

Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder (OCD) is a chronic, severely distressing psychiatric condition affecting 2-3% of the population, characterized by intrusive thoughts and repetitive behavioral or mental rituals.

Neurobiology & Pathophysiology

OCD arises from dysregulation within the Cortico-Striato-Thalamo-Cortical (CSTC) loops, particularly involving hyperactive parallel circuits connecting the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), and caudate nucleus of the striatum:

• In healthy individuals, the caudate nucleus acts as an inhibitory filter ('gatekeeper'), screening out irrelevant intrusive thoughts generated by the orbitofrontal cortex.
• In OCD, striatal gating fails, leading to unchecked orbitofrontal hyperactivation. The patient experiences an unrelenting subjective feeling that 'something is wrong' or catastrophic danger is imminent (obsession), compelling repetitive motor or mental actions (compulsions) to temporarily neutralize anxiety.

                  CSTC LOOP HYPERACTIVITY IN OCD

   ┌────────────────────────────────────────┐
   │    Orbitofrontal Cortex (OFC) &        │ <──── Sustained Error Signal
   │   Anterior Cingulate Cortex (ACC)      │       ('Something is terribly wrong!')
   └───────────────────┬────────────────────┘
                       │ Direct Excitatory Pathway
                       ▼
   ┌────────────────────────────────────────┐
   │       Ventral Striatum / Caudate       │ <──── Defective Gating / Filtering
   │       (Failure of normal inhibition)   │
   └───────────────────┬────────────────────┘
                       │
                       ▼
   ┌────────────────────────────────────────┐
   │          Thalamus Activation           │ ───> Drives Compulsive Rituals
   │     (Disinhibited cortical drive)      │      (Temporary anxiety reduction)
   └────────────────────────────────────────┘

---

DSM-5 Diagnostic Criteria for OCD

Diagnosis requires the presence of obsessions, compulsions, or both, meeting the following operational thresholds:

1. Obsessions: Defined by both:
   • Recurrent and persistent thoughts, urges, or images that are experienced as intrusive and unwanted, causing marked anxiety or distress.
   • The individual attempts to ignore, suppress, or neutralize them with another thought or action (i.e., by performing a compulsion).
   • Common themes: Contamination (dirt, germs), pathological doubt and harm (leaving stoves on, fear of hitting pedestrians), symmetry and ordering, taboo sexual, religious, or aggressive thoughts.
2. Compulsions: Defined by both:
   • Repetitive behaviors (e.g., handwashing, ordering, checking locks) or mental acts (e.g., praying, counting, silently repeating words) that the individual feels driven to perform in response to an obsession or according to rigidly applied rules.
   • Behaviors or mental acts are aimed at preventing or reducing anxiety or preventing a dreaded event; however, these acts are either clearly excessive or not realistically connected to what they are designed to neutralize.
3. Time-Consuming or Impairing: The obsessions or compulsions are time-consuming (taking >1 hour per day) or cause clinically significant distress or functional impairment.
4. Insight Specifier:
   • Good/fair insight: Recognizes beliefs are definitely or probably not true.
   • Poor insight: Believes beliefs are probably true.
   • Absent insight / delusional beliefs: Completely convinced that OCD beliefs are true (e.g., convinced the house will burn down if the switch is not touched 20 times).

---

Evidence-Based Management of OCD

1. First-Line Psychotherapy: Exposure and Response Prevention (ERP)

• Exposure and Response Prevention (ERP), a specialized form of CBT, represents the non-pharmacologic gold standard for OCD.
• Mechanism: Patients are systematically, hierarchically exposed to stimuli that trigger obsessional distress (e.g., touching a public restroom doorknob) while strictly refraining from engaging in compulsive rituals (e.g., washing hands).
• Outcome: Over sustained exposure sessions, the patient learns that anticipated catastrophes do not materialize and that anxiety naturally habituates without ritualistic neutralization.

2. First-Line Pharmacotherapy: High-Dose SSRIs

Pharmacotherapy for OCD differs fundamentally from the treatment of major depressive disorder (MDD) in two critical ways: higher dosing and longer latency to response.

                  SSRI DOSING COMPARISON: OCD VS. MAJOR DEPRESSION

   Medication        Standard MDD Dosing Range    Target OCD Dosing Range     Max Daily Dose in OCD
   ═══════════════════════════════════════════════════════════════════════════════════════════════════
   Fluoxetine        20 - 40 mg daily             60 - 80 mg daily            80 mg daily
   ───────────────────────────────────────────────────────────────────────────────────────────────────
   Sertraline        50 - 100 mg daily            150 - 200 mg daily          200 mg daily (up to 250-400 mg off-label)
   ───────────────────────────────────────────────────────────────────────────────────────────────────
   Paroxetine        20 - 40 mg daily             40 - 60 mg daily            60 mg daily
   ───────────────────────────────────────────────────────────────────────────────────────────────────
   Fluvoxamine       100 - 200 mg daily           150 - 300 mg daily          300 mg daily (FDA-approved for OCD)
   ═══════════════════════════════════════════════════════════════════════════════════════════════════

• Extended Trial Duration: While depression often responds within 4-6 weeks, OCD requires 10 to 12 weeks at the maximum tolerated dose before determining treatment efficacy. Premature discontinuation or dose reduction is a frequent clinical pitfall.

3. Second-Line & Augmentation Strategies

• Atypical Antipsychotic Augmentation: In patients with partial response to maximum-dose SSRI therapy after 12 weeks, augmenting with low-dose Aripiprazole (2.5-10 mg daily) or Risperidone (0.5-2 mg daily) produces meaningful symptom reduction in 30-50% of treatment-refractory patients.
• Clomipramine: A tricyclic antidepressant (TCA) with potent, non-selective serotonin reuptake inhibition. Highly efficacious for OCD, but relegated to second-line status due to anticholinergic adverse effects (dry mouth, urinary retention, severe constipation), alpha-1 antagonism (orthostatic hypotension), lowered seizure threshold, and fatal cardiotoxicity in overdose (QTc prolongation, fatal arrhythmias).

---

Somatic Symptom and Related Disorders

Somatic symptom disorders are common in primary care, representing up to 10-20% of adult outpatient visits. Patients experience prominent, distressing physical symptoms accompanied by disproportionate psychological distress, healthcare utilization, and functional impairment.

               SPECTRUM OF SOMATIC SYMPTOM & RELATED DISORDERS

   Condition                  Core Diagnostic Feature                        Physical Symptoms Present?
   ════════════════════════════════════════════════════════════════════════════════════════════════════════
   Somatic Symptom Disorder   ≥1 distressing somatic symptom + excessive,    YES (Prominent pain, fatigue,
   (SSD)                      disproportionate thoughts/anxiety/behaviors    GI complaints >6 months)
   ────────────────────────────────────────────────────────────────────────────────────────────────────
   Illness Anxiety Disorder   Preoccupation with having/acquiring a serious  MINIMAL OR NONE (Preoccupation
   (formerly Hypochondriasis) illness; excessive checking or avoidance       with disease concept itself)
   ────────────────────────────────────────────────────────────────────────────────────────────────────
   Conversion Disorder        ≥1 symptom of altered voluntary motor or       YES (Neurological deficits
   (Functional Neurological)  sensory function with clinical INCOMPATIBILITY incompatible with anatomy)
   ────────────────────────────────────────────────────────────────────────────────────────────────────
   Factitious Disorder        Falsification of physical/psychological signs  YES (Deceptive production;
                              WITHOUT external secondary gain                internal sick role reward)
   ────────────────────────────────────────────────────────────────────────────────────────────────────
   Malingering                Intentional production/feigning of symptoms    VARIABLE (External secondary
   (Not a mental disorder)    motivated by EXTERNAL INCENTIVES (money, drugs) gain: disability, evasion)
   ════════════════════════════════════════════════════════════════════════════════════════════════════

1. Somatic Symptom Disorder (SSD)

• DSM-5 Criteria:
  • One or more somatic symptoms that are distressing or result in significant disruption of daily life.
  • Excessive thoughts, feelings, or behaviors related to the somatic symptoms, manifested by at least one of:
    1. Disproportionate and persistent thoughts about the seriousness of one's symptoms.
    2. Persistently high level of anxiety about health or symptoms.
    3. Excessive time and energy devoted to these symptoms or health concerns.
  • State of being symptomatic is persistent (typically >6 months).
• Primary Care Management Framework (The 'C-Care' Strategy):
  1. Regularly Scheduled, Predictable Visits: Schedule brief, fixed-interval visits (e.g., every 4 to 6 weeks) regardless of whether symptoms are currently flared. This decouples clinical access from acute symptom severity, removing subconscious reinforcement of the sick role.
  2. Validate the Suffering: Acknowledge that the patient's symptoms and suffering are genuine ('I believe that your pain is real and distressing, even though tests have not shown tissue damage'). Never dismiss symptoms as 'all in your head.'
  3. Perform a Brief, Focused Physical Exam: Examine the symptomatic area at each encounter. This builds therapeutic trust and provides physical reassurance without incurring laboratory costs.
  4. Avoid Low-Yield Diagnostics & Polypharmacy: Resist ordering redundant imaging, laboratory panels, or invasive procedures to appease health anxiety. Avoid habit-forming medications (sedatives, opioids).
  5. Focus on Function over Cure: Transition therapeutic goals from symptom eradication to functional rehabilitation, pain coping, and activities of daily living.
  6. Engage in Psychotherapy: Recommend Cognitive Behavioral Therapy (CBT) framed as an active tool to manage symptom-related stress and restore functional independence.

2. Illness Anxiety Disorder

• Preoccupation with having or acquiring a serious, undiagnosed illness.
• Somatic symptoms are absent or only mild in intensity.
• High health anxiety with excessive illness-related behaviors (repeatedly checking skin, monitoring pulse, compulsive web searching) or maladaptive avoidance (avoiding doctor appointments or hospitals).
• Illness preoccupation persists for ≥6 months.
• Distinguishing factor from SSD: In SSD, the patient is incapacitated by distressing physical symptoms; in Illness Anxiety Disorder, the distress arises from the fear of having a disease despite minimal or absent bodily symptoms.

3. Conversion Disorder (Functional Neurological Symptom Disorder)

Conversion disorder involves one or more symptoms of altered voluntary motor or sensory function that demonstrate clear clinical incompatibility between the symptom and recognized neurological disease.

Diagnostic 'Positive' Signs on Physical Examination

Diagnosis does not rely solely on excluding disease; it requires positive clinical signs demonstrating internal inconsistency and preservation of underlying physiological pathways:

• The Hoover Sign (Functional Lower-Extremity Weakness):
  • Procedure: With the patient supine, the examiner places a hand under each heel. The patient is asked to perform voluntary hip extension of the paretic leg (which displays weakness). Next, the patient is asked to flex the contralateral, normal hip against resistance.
  • Positive Hoover Sign: During contralateral hip flexion, the examiner feels strong, involuntary downward pressure from the paretic heel due to the normal synergistic extension reflex. This confirms that pyramidal corticospinal motor pathways are anatomically intact.
• Tremor Entrainment Test (Functional Tremor):
  • A functional limb tremor changes frequency or rhythm to match the voluntary rhythmic tapping of the unaffected limb, or the tremor stops completely when the patient concentrates on tapping.
• Give-Way (Collapsing) Weakness:
  • Sudden, jerky cessation of muscle resistance during manual muscle testing, rather than the smooth, sustained weakness of organic upper or lower motor neuron lesions.
• Tubular (Tunnel) Visual Fields:
  • Constricted visual fields that maintain an identical visual field diameter when tested at 1 meter and 2 meters, violating the geometric laws of optical dispersion.
• Psychogenic Non-Epileptic Seizures (PNES):
  • Clinical features distinguishing PNES from epileptic seizures include: closed eyes with active resistance to manual eyelid opening, preserved pupillary light reflexes, prolonged ictal duration (>15-30 minutes), asynchronous thrashing, side-to-side head shaking, pelvic thrusting, absence of post-ictal stertorous breathing, and normal ictal EEG without epileptiform activity.

Management of Conversion Disorder

• Delivering the Diagnosis: Present the diagnosis transparently and empathetically. Explain that the neurological 'hardware' (brain, spinal cord, nerves) is structurally intact, but the 'software' (functional brain signaling) is experiencing temporary disruption.
• Physical & Occupational Therapy: Early referral for physical therapy focusing on functional movement retraining, redirection of attention, and progressive mobility without reinforcing abnormal gait patterns.
• Psychotherapy: CBT to explore comorbid stressors, alexithymia, and anxiety.